Laotian version of lorlatinib/lorlatinib: an affordable new option for lung cancer treatment

In the international pharmaceutical market, a number of Lao-made generic drugs of Lorlatinib (Lorlatinib) have emerged. They are produced by well-known pharmaceutical companies such as Laos Lucius Pharmaceuticals, Daxiong Pharmaceuticals, ASEAN Pharmaceuticals, United Pharmaceuticals, and Element Pharmaceuticals. These generic drugs are highly similar in chemical composition to the brand-name drugs, although they may differ slightly in strength, manufacturer, and pricing.

Larlatinib is a prescription drug and must be used under the guidance of a doctor. Lorviqua treatment should be prescribed and supervised by a physician with extensive experience in cancer drug treatment. Before starting treatment, a patient's cancer should undergo genetic testing to confirm the presence of genetic mutations that affect ALK.

In the international market, the Lao version of lorlatinib has provided more patients with an effective and economical treatment option with its diverse specifications (such as100 mg 30 tablets, 25 mg 30 tablets, etc.) and affordable price (approximately 1,000 to 3,000 yuan per box, the price may change due to exchange rate fluctuations).

Lorlatinib, as a new generation of ALK inhibitors, is more effective than the second generation of drugs at the biochemical and cellular levels. Studies have shown that lorlatinib exhibits powerful anti-tumor effects when previous ALK inhibitor treatments have failed. Especially in patients with previously treated CNS disease, including those with leptomeningeal disease, lorlatinib has shown significant intracranial efficacy. Given its efficacy and safety, lorlatinib has become the treatment of choice for ALK-positive patients who have failed one or more ALK inhibitors.